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sonal (P = 0.0034), and output demand (P = 0.0174) subscales.
For the 150-mg group, the reduction in WLQ total index score
approached signiﬁcance (−2.9 [0.9]; P = 0.0545) and the mental-
interpersonal improved signiﬁcantly compared with placebo (P
= 0.0057). CONCLUSION: Reductions in hot ﬂush frequency
and severity and improved sleep and mood are accompanied by
signiﬁcant improvement in work productivity in postmenopausal
women treated with DVS.
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OBJECTIVES: To evaluate the cost-effectiveness and budget
impact of vaccinating a single birth cohort of girls 11 years of
age with Gardasil, a novel vaccine against human papilloma
virus (HPV), in the presence of the current triennial cervical
screening programme. METHODS: A lifetime Markov model of
the incidence and prevalence of cervical dysplasia and cancer was
constructed from New Zealand cervical cancer registrations and
ﬁve-year survival plus the incidence of dysplasia estimated from
analyses of screening histories of 28,000 women. Costs of dys-
plasia, cervical cancer and genital warts were obtained from local
sources and health state utilities were taken from published
sources. Efﬁcacy was taken from several recent phase III clinical
trials (FUTURE). The model was internally validated against the
prevalence of dysplasia. RESULTS: Assuming lifetime protection
and 79% uptake of 3 doses, HPV vaccination would prevent 140
cervical cancer cases and 42 deaths over the lifetime of the vac-
cinated cohort. At a unit vaccine price per dose of $NZ128.50
and 5% annual discount rate, the cost per QALY in the base case
analysis is less than $NZ25,000 from either a health care or a
Government perspective. The annual budget impact of vaccina-
tion for the Government is $NZ10.5M. Catch-up vaccination
strategies for women age 12 to 26 y are more cost effective. These
ﬁndings are sensitive to the reduction in quality of life that
accompanies abnormal cytology or histology ﬁndings; vaccine
efﬁcacy; HPV genotype distribution; vaccine uptake and 
duration of protection. CONCLUSION: When a universal 
programme of HPV vaccination is added to current clinical
screening and management of dysplasia and cervical cancer, over
the lifetime of a birth cohort the cost required to provide each
additional quality adjusted life year is very modest by interna-
tional standards.
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OBJECTIVES: To examine the incidence of statin initiation in
patients with type 2 diabetes, medication compliance rates for
both antidiabetic and statin therapies, and the impact of patient
medication behavior on disease outcomes. METHODS: The Cal-
ifornia Medicaid program (Medi-Cal) claims data collected
during the period of January 1995 to December 2004 was ana-
lyzed. A total of 4222 patients with type 2 diabetes were included
in the study. Medication compliance was measured using Pro-
portion of Days Covered (PDC) in each quarter of the study
period. Descriptive analyses were performed to: 1) examine ini-
tiation of statin therapy and its change over time; and 2) compare
long-term medication compliance to statin and to antidiabetic
agents. A marginal structural model was employed to examine
the impact of medication compliance to statin therapy on car-
diovascular events. The effects of compliance on hospitalization
and total medical costs were estimated by generalized estimating
equations (GEE). RESULTS: Statin therapy was initiated by
2.71% of diabetic patients in 1996, rising to 18.08% in 2003.
Medication compliance to statin therapy was high (PDC = 0.83,
SD = 0.234) during the ﬁrst quarter of statin treatment. However,
patient compliance dropped sharply from the second quarter
(PDC = 0.63, SD = 0.382) and the medication compliance at the
end of the ﬁrst year of the treatment was decreased to 0.56. Over
the 30 quarters, patients were less likely to comply with statin
therapy than with antidiabetic treatment (approximately 35%
difference). Hispanic patients and patients with complicated
medication regimens were more likely to exhibit poor compli-
ance to statin therapy. Poor compliance to statin therapy was sig-
niﬁcantly associated with increased cardiovascular risk events (p
< 0.01) and hospitalization in patients with type 2 diabetes (p <
0.01). CONCLUSION: Prescribing of statins in diabetic popu-
lations has improved in recent years, but long-term medication
compliance to statin therapy and antidiabetic medications in the
California Medicaid population remains problematic.
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OBJECTIVES: To evaluate the impact of persistence with anti-
TNF treatment on rheumatoid arthritis (RA)-related health care
costs among RA patients. METHODS: A retrospective study, 
utilizing the PharMetrics managed-care claims database, was
conducted. The ﬁrst anti-TNF (inﬂiximab, etanercept, or adali-
mumab) plus methotrexate encounter among RA patients
between January 1, 2001 and January 1, 2004 was identiﬁed.
Patients were required to have a minimum of 12-months of con-
tinuous plan eligibility prior to and following their index bio-
logic date. Persistence (%) was deﬁned as the number of days
between their ﬁrst biologic prescription and the last biologic
encounter, divided by 365 and multiplied by 100. Two mutually
exclusive cohorts were developed based on their level of anti-
TNF persistence: individuals who were persistent ≥80%; and
those who were persistent <80%. RA-related costs were com-
pared between two groups. RESULTS: A total of 1242 patients
were included, 339 patients (27.3%) with a persistency ratio
<80% and 903 (72.7%) patients with a persistency ratio ≥80%.
Over two-thirds of the patients were females and the mean age
was 50 years. Other than pharmacy cost, higher persistence
resulted in lower non-pharmacy medical costs ($3091 versus
$4601). The higher persistence cohort had signiﬁcantly lower
cost in all non-pharmacy cost categories: inpatient services,
physician services, other out-patient services, emergency room,
and lab costs as compared to the lower persistence cohort. After
adjusting for confounding variables (age, gender, co-morbidity,
and disease staging), patients in the higher persistence group 
had a signiﬁcant lower non-pharmacy cost with a lower co-
morbidity. There was no difference in age, gender, and disease
staging between the groups. CONCLUSION: This study indi-
cates that while higher pharmacy costs were associated with
